Marker Therapeutics, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
2450 HOLCOMBE BLVD, HOUSTON, TX, 77021
Mailing Address
2450 HOLCOMBE BLVD, HOUSTON, TX, 77021
Phone
(713) 400-6400
Fiscal Year End
1231
EIN
880277072
Financial Overview
FY2025
-$10.73M
Net Income
$18.56M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | March 20, 2026 | View on SEC |
| 8-K Current report of material events | March 19, 2026 | View on SEC |
| 10-K Annual financial report | March 18, 2026 | View on SEC |
| 8-K Current report of material events | February 9, 2026 | View on SEC |
| 4 Insider stock transaction report | November 19, 2025 | View on SEC |
| 4 Insider stock transaction report | November 19, 2025 | View on SEC |
| 4 Insider stock transaction report | November 19, 2025 | View on SEC |
| SCHEDULE 13D/A Beneficial ownership amendment | November 17, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 8-K Current report of material events | November 14, 2025 | View on SEC |
Annual Reports
10-K
March 18, 2026
- Developing advanced MAR-T cell therapies to fight cancer by recognizing multiple tumor-associated antigens.
- Lead product candidate, MT-401, is in a Phase 1 clinical trial for acute myeloid leukemia (AML).
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.